Curonz is a clinical stage Neurotherapeutics company with the vision to transform the Quality of Life of severely neurologically affected young patients.

Our approach involves a body and mind boosting drug therapy with a modified naturally occurring molecule named NRP2945 that controls seizure activity with simultaneous memory improvement profiles in patients diagnosed with epileptic encephalopathy syndromes like Lennox-Gastaut Syndrome. NRP2945 exerts its activity via agonism of a novel CXCR4 receptor complex in an ultra-potent manner with no off-target effects.

Another strong benefit derives from the minimal adverse event profile displayed by our peptide drug NRP2945. Subcutaneous injections of fully formulated NRP2945 administered every-other-day provide for a well-tolerated administration scheme.


The NRP Discovery

A phenotypic brain tissue screen to monitor neuronal migration was used to initally screen compounds for their potential to generate neural outgrowth.

read more

Clinical Trials

Curonz has completed a successful Phase I safety trial in healthy volunteers. We recently completed a small Phase II trial in patients with Absence Epilepsy.

read more

Lennox Gastaut Syndrome

Lennox-Gastaut Syndrome (LGS) is a refractory childhood epilepsy. In the US less than 20,000 children are diagnosed. NRP2945 has been awarded Orphan Drug Status by the FDA for LGS.

read more